Bonobo Bornean orangutan Bos Brown anole Brown bat Brown woolly monkey Carolina anole Chimpanzee Chinese hamster Chinese tree shrew
Dog Geoffroy's spider monkey Goat Horse Mouse Rat Short-tailed opossum Western gorilla White-lipped tamarin Xenopus
It is intended for research use only
The total assay time is less than 2.5 hours
The kit measures hsa-miR-93-5p isolated from human blood
Assay format is 96 wells
Standard is synthetic miRNA-based
Components of the kit are provided ready to use, concentrated or dried
Cardiovascular disease, Oncology, Renal disease
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
Recent studies indicate that miRNAs function as oncogenes and tumor suppressors. Dysregulated miRNAs can promote tumorigenesis and cancer progression and even result in poor cancer prognosis. Cancer-specific miRNAs are present in extracellular body fluids, and may play an important role in crosstalk between cancer cells and surrounding normal cells.
hsa-miRNA-93 is a member of the miR-106b-25 cluster. hsa-miR-93 has been reported to be upregulated and have a promoting role in several cancer types. Increasing body of evidence indicates that the dysregulation of hsa-miR-93-5p is associated with development of multidrug resistance in various types of cancer.
miRNAs are also key regulators of many cellular events in pathogenesis of atherosclerosis. hsa-miR-93-5p is specifically associated with coronary artery disease. Several groups have reported potential utility of miRNAs as biomarkers in diagnosis and prediction of cardiovascular disease.
Moreover, hsa-miR-93-5p might help to assess pathophysiological changes associated with chronic kidney disease and potential bone-specific and vascular risks as well as therapy aspects in pacients with chronic kidney disease.
References to Summary
References to miR-93-5p
SUETA, Aiko, et al. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. Oncotarget, 2017, 8.41: 69934.
LI, Nana, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death & Disease, 2017, 8.5: e2796.
WANG, Shi Jun, et al. MicroRNA 93 5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression. Oncology Letters, 2017, 13.2: 722-730.
GAMBARI, Roberto, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology. International journal of oncology, 2016, 49.1: 5-32.
HE, Yu; YU, Bo. MicroRNA 93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells. Experimental and Therapeutic Medicine, 2017, 13.5: 2003-2011.
OHTA, Katsuya, et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget, 2015, 6.5: 3211.
CHEN, Rui, et al. MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide. Biology open, 2016, 5.6: 669-677.
JOHN, F. O., et al. miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. International journal of cardiology, 2016, 224: 310-316.
ULBING, M., et al. MicroRNAs 223-3p and 93-5p in patients with chronic kidney disease before and after renal transplantation. Bone, 2017, 95: 115-123.